key: cord-0767375-murjnjoe
authors: El Adam, Shiraz; Zou, Macy; Kim, Shinhye; Henry, Bonnie; Krajden, Mel; Skowronski, Danuta M
title: SARS-CoV-2 mRNA vaccine effectiveness in healthcare workers by dosing interval and time since vaccination: test negative design, British Columbia, Canada
date: 2022-04-15
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofac178
sha: f500a5d81e65dc996c79f7b7b004d1ec6a9b5a56
doc_id: 767375
cord_uid: murjnjoe

BACKGROUND: One- and two-dose mRNA vaccine effectiveness (VE) estimates against SARS-CoV-2 infection by dosing interval and time since vaccination were assessed among healthcare workers (HCWs) in publicly-funded acute and community (non-residential) healthcare facilities in British Columbia, Canada. METHODS: A test-negative design was used with (6:1) controls matched to cases on epidemiological week of SARS-CoV-2 test date. mRNA vaccination was defined by receipt of the first dose ≥21 days or second dose ≥14 days before test date. HCWs ≥18 years old tested for SARS-CoV-2 between epi-weeks 3-39 (January 17-October 2,2021) were included, when varying dosing intervals and a mix of circulating variants-of-concern contributed, including Delta dominance provincially from epi-week 31 (August 1). RESULTS: Single- and two-dose analyses included 1,265 and 1,246 cases, respectively. Median follow-up period was 49 days (interquartile range: 34-69) for single-dose and 89 days (interquartile range: 61-123) for two-dose recipients, with 12%, 31% and 58% of second doses given 3-5, 6 or ≥7 weeks after the first. Adjusted mRNA VE against SARS-CoV-2 was 71% [95% CI: 66, 76] for one dose and 90% [95% CI: 88, 92] for two doses, similar with two heterologous mRNA doses (92%;[95% CI: 86, 95]). Two-dose VE remained >80% at ≥28 weeks post-second dose. Two-dose VE was consistently 5-7% higher with ≥7-week versus 3-5-week interval between doses. CONCLUSIONS: In a HCW population, we report substantial single-dose and strong and sustained two-dose mRNA vaccine protection, the latter maintained at least seven months. Findings inform longer interval between doses, with global health and equity implications.

Healthcare workers (HCWs) have been at the frontlines of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. With high potential for exposure 1 , and to mitigate the risk to themselves and their patients, HCWs in Canada were also amongst the first prioritized for vaccination. Two mRNA vaccines, including BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) were first authorized in Canada on December 9 (epi-week 50) and December 23 (epiweek 52) of 2020, respectively, according to a two-dose schedule spaced 3-4 weeks apart. 2 In the province of British Columbia (BC), Canada, HCW vaccination began December 15, 2020 (epidemiological-week 51) at the manufacturer-recommended interval of 3-4 weeks between doses. In response to elevated COVID-19 activity and scarce vaccine supply a modified 5-week dosing interval was announced in epi-week 52. A 6-week interval was subsequently recommended in late-January (epi-week 4) of 2021, maintained until early-March (epi-week 9) when Canada's National Advisory Committee on Immunization (NACI) recommended an even longer 16- week interval between first and second doses. 3 As vaccine supply improved, the dosing interval was reduced in BC to 8 weeks in late-May (epi-week 21), 7 weeks in late-July (epi-week 30) and 4 weeks in August (epi-week 32) but with a preferred interval of not less than 6 weeks still emphasized. 4 Immunogenicity studies among HCWs in BC and Ontario, Canada have compared antibody response at 3-4-week versus 6-7-week interval 5 and at 3-6-versus 8-16-week 6 interval between first and second doses. Both showed improved antibody levels at their longer interval but antibody thresholds for protection have not been established. In population-based evaluation of A c c e p t e d M a n u s c r i p t vaccine effectiveness (VE) using the test-negative design (TND) in BC and Quebec, Canada, protection was lower at 3-4-and 5-6-week compared to 7-8- week interval between doses, stable thereafter. 7 To measure the degree and duration of one-and two-dose mRNA VE against SARS-CoV-2 infection in HCWs, and to further explore the effects of extended dosing interval, we applied the TND to acute-care and community-based HCWs in BC, Canada. We also assessed one-and twodose VE by vaccine type (BNT162b2 and mRNA-1273), age group, sex, and level of patient care.

We used the TND with incidence density sampling, matching test-negative controls 6:1 to testpositive cases based on epidemiological week (epi-week) of the nucleic acid amplification test date. For HCWs with multiple negative tests throughout the study period, one test per epi-week was randomly selected. Further HCW case or control contribution was censored on the date of the first positive test.

Outcome and vaccine status definition VE was estimated against any infection. Testing was mostly symptom-based by nasopharyngeal swab but available data do not support VE stratification by symptom status. Gargle (saliva) specimens were available but not widely or systematically used in HCWs. Rapid antigen tests were not broadly deployed during the analysis period.

A c c e p t e d M a n u s c r i p t SARS-CoV-2 vaccination was publicly-funded and encouraged but not mandatory for HCWs in BC during the study period. Vaccination status was defined by the time between the last vaccine dose and the specimen test date, the latter defined by the earliest of test order or result date.

Given analyses based upon testing rather than onset date, we incorporated additional lag-time, in addition to the expected timeline for vaccine-induced immunity following each dose. 8 For primary VE estimation, single-dose vaccine status was defined by ≥21 days and two-dose status was defined by ≥14 days between vaccination and test-date. Specimens with a first dose <21 days prior or a second dose <14 days prior were excluded. Unvaccinated HCWs were those tested who received no vaccine dose on or before the test date. For single-dose analyses, specimens collected on/after second-dose were excluded. For two-dose analyses, specimens collected on/after a single dose only were excluded.

Single-and two-dose VE analyses spanned epi-weeks 3-30 (January 17-July 31, 2021) and epiweeks 9-39 (February 28-October 2), respectively. However, analyses of VE at longer durations after the second dose were restricted to more recent study periods to enable sufficient number of vaccinated cases and controls with that amount of follow-up. For example, to assess VE at [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] weeks post-second dose, analyses were restricted to epi-weeks 20-39 (May 16-October 2) and at ≥28 weeks post-vaccination were restricted to epi-weeks 35-39 (August 29-October 2).

Although the genetic characterization of case viruses among HCWs was not available for the current analysis, a mix of circulating variants of concern (VOC) were detected in the general BC A c c e p t e d M a n u s c r i p t population including working-age adults ≥18-years-old. 7, 9 Alpha and Gamma variants were first detected in January and February 2021, respectively, increasing to unique co-dominance through May and June, but with Delta appearing in April, increasing through July and comprising almost sole-detection provincially from August 1, 2021 (epi-week 31) through the rest of the analysis period. 

All HCWs within the WHITE database ≥18 years (at test date), hired before October 1 st 2021 (epi-week 39), and tested for SARS-CoV-2 within the analysis period were included. A broad array of HCW occupations were included (e.g. physicians, paramedics/emergency responders, nurses, pharmacists, therapists, technicians, clinical, service, research, and administrative/managerial staff) from publicly-funded acute (e.g. hospitals, emergency departments, urgent care) and community-care settings (e.g. home or ambulatory care services).

Excluded HCWs were those who tested positive before the analysis period or with missing, inconclusive or invalid information for vaccination or test details, age, sex, or HA. Also excluded were HCWs tested for a possible workplace exposure/cluster or who worked in LTCF, assisted living, hospice or correctional facilities (residential facilities), where cluster testing/screening was more likely. Due to smaller numbers, specimens from recipients of non-mRNA vaccines were also excluded.

The odds of vaccination among SARS-CoV-2 test-positive versus test-negative specimens was compared through the odds ratio (OR) using multivariable conditional logistic regression, with the matching epi-week for cases and controls as stratum. Single-and two-dose mRNA VE was A c c e p t e d M a n u s c r i p t derived as [(1 -OR adjusted ) x100] with 95% confidence interval (CI). Covariates included age group (18-29, 30-39, 40-49, 50-59, ≥60 years); sex (male, female); and HA of HCW residence (five categories). VE was separately estimated by mRNA product, age, sex and, to compare with estimates previously published for VCHA, 12 separately for VCHA and FHA and other HAs combined provincially. We also assessed two-dose VE among those classified as providing direct patient care (including all categories of nurses) or service providers (e.g. food, transportation, cleaning, laundry, maintenance services) based upon the first-mentioned job, recognizing >90% of HCWs had just one job. 

Study does not include factors requiring patient consent. A c c e p t e d M a n u s c r i p t

Among vaccinated participants, 92% single-dose and 83% two-dose HCWs received BNT162b2.

Among all HCWs in the WHITE database (without exclusions) the percentage who had received at least one mRNA vaccine dose was 30% in epi-week 3 and 91% in epi-week 30 (end of singledose study period) (Supplementary_Figure_1). The percentage who had received a second mRNA vaccine dose was 2% in epi-week 3, increased to 24% by epi-week 8 and remained stable at about 25% between epi-weeks 9-17, increasing gradually thereafter to 54%, 86% and 92% by epi-weeks 22, 30 and 39, respectively. Among the matched two-dose recipients for the primary analysis (n=6372), the interval between doses was 3-5, 6 or ≥7 weeks among 762 (12%), 1963 (31%) and 3644 (58%), respectively (Table_1). In simultaneous assessment of VE by interval between doses and time since second dose, point estimates of VE were consistently 5-7% (absolute) higher among those vaccinated with interval ≥7 weeks (91-95%) than 3-5 weeks (85-88%) between doses, but also with overlapping confidence intervals (Figure_2; Supplementary_Table_3) . For neither interval did VE decline with time since vaccination out to at least 16 weeks. Among those twice vaccinated at a 6-week schedule, VE initially approximated that of the ≥7-week dosing interval (98%), but aligned more closely with the shorter 3-5-week interval by 10-15 weeks (85%) and 16-27 weeks (86%), A c c e p t e d M a n u s c r i p t declining at ≥28 weeks (79%) post-vaccination, accompanied by wide and overlapping confidence intervals.

Compared to our overall adjusted two-dose mRNA VE of 90% [95% CI: 88, 92], VE with restriction to HCWs in residential facilities was slightly lower at 82% [95% CI: 76, 87]. Of these HCWs in residential facilities, however, median follow-up was longer (126 days) with 24% revaccinated at 3-5-week interval and 75% at 3-6-week interval following the first dose, representing more at shorter intervals between doses than in our primary analysis (12% and 43%, respectively).

In this observational study, one dose of mRNA vaccine provided substantial protection and two doses were associated with strong and sustained reduction of SARS-CoV-2 infection risk among HCWs in BC, Canada. Overall, mRNA VE against any SARS-CoV-2 infection was about 70% for a single dose across median follow-up of 7 weeks (IQR: ~5-10 weeks) and 90% for two doses across median follow-up of ~13 weeks (IQR: ~9-18 weeks). VE estimates were similar in sensitivity and sub-group analyses, slightly higher for mRNA-1273 than BNT162b2 for one-dose (77% vs. 70%) and two-dose (93% vs. 89%) recipients but with overlapping confidence intervals. Two-dose VE of ~90% or more against infection was maintained to at least 16 weeks and was 80% or more to at least 28 weeks. VE trended higher among HCWs twice vaccinated at longer interval of ≥7 weeks vs. 3-5 weeks after the first dose, consistent with earlier population-A c c e p t e d M a n u s c r i p t based findings. 7 Importantly, strong protection was sustained across follow-up spanning a mix of circulating VOC, including earlier Alpha and Gamma, and later Delta, dominance.

Recognizing underlying variability in study conditions when comparing overall estimates, our findings, predicated on generally longer dosing intervals and follow-up periods, nevertheless align well with estimates elsewhere, particularly with studies using similar methods. For instance, in a TND study with epi-week matching from Quebec, Canada, 15 Our findings further align with prospective cohort studies from the US and the UK. 16, 17 In prospective evaluation against any SARS-CoV-2 infection in the US, 16 19 Retrospective cohort analyses may be subject to the precarious assumption that absence of a test result equates with absence of infection. Such assumption may be variably true depending upon access and completeness of testing by jurisdiction but overall introduces greater risk of selection bias compared to more systematic or standardized likelihood of testing among prospective cohort or TND approaches. Other differences in prevailing conditions and methods or context should also be taken into account when comparing VE estimates across studies.

In addition to our generally longer follow-up periods, second-dose scheduling recommendations in Canada facilitated assessment of VE at intervals longer than specified by manufacturers.

Findings from this study reassuringly add to other evidence [5] [6] [7] in reinforcing policy recommendations to extend the interval between mRNA doses to ≥8 weeks by NACI in Canada 2 and subsequently by the Centers for Disease Control and Prevention in the United States. 20 We observed higher VE at longer interval of ≥7 weeks between doses, also consistent with accumulating epidemiological 7,21 and immunological evidence. 5, 6, 22 Protection was more variable over time among HCWs revaccinated at 6-week versus 3-5 or ≥7-week interval. The pattern of decline in two-dose VE among those re-vaccinated at 6-week but not shorter or longer dosing intervals may reflect differential exposure risk and/or testing behaviours among HCWs A c c e p t e d M a n u s c r i p t prioritized for earlier vaccination and then revaccinated six weeks later in January/February 2021 compared to most who received their first and second doses later in the year and at longer interval between. We also acknowledge smaller sample size with greater stratification, particularly among those re-vaccinated at the shortest 3-5-week interval between doses, with broadly overlapping confidence intervals.

With calendar time being among the most important confounders in observational VE studies, an important strength of this study is the matching of cases and controls on the epidemiological week of testing in addition to covariate adjustment for age, sex and geographic region. However, this study also has limitations, mainly related to its observational design and use of surveillancebased data subject to misclassified, missing or incomplete information. Vaccine status based on PIR record and case ascertainment based on specific nucleic acid detection mitigated vaccine or outcome misclassification. We were unable to adjust for comorbidities or other potential confounders (such as race/ethnicity) due to data limitations and our findings were based on any SARS-CoV-2 infection without regard to symptoms or severity. Given the young profile of our study population, comorbidity and severe outcomes are less contributory but our outcome of any infection may have under-estimated VE compared to clinical trials based on symptomatic infection. 8, 23, 24 We attempted to standardize for the testing indication by excluding HCWs screened for workplace exposure or employed by residential care facilities where both vaccination and test-positivity rates were more likely to differ. However, these efforts may have been incomplete and would further limit generalizability of findings. Provincial policy did not otherwise include routine screening of HCWs in acute or community-care settings (or based on vaccine status), but we cannot rule out such testing. Although our study population was restricted A c c e p t e d M a n u s c r i p t to HCWs and we further stratified based on broad worker categories, differential exposure risk may still exist between vaccinated and unvaccinated workers. The analysis of longer time since vaccination (≥28 weeks), was confounded by VOC circulation with Delta dominance during that period (Aug 29 -Oct 2); however, in population-based analyses, two-dose VE against Delta did not meaningfully differ from Alpha among adults in BC or Quebec, Canada. 7 We cannot reliably comment upon the extent to which our observations may extend to other variants that have further evolved genetically and antigenically away from the vaccine strain, such as the morerecently emergent Omicron VOC. Regardless, understanding the potential duration of two-dose protection under conditions of relatively greater or lesser genetic match between the vaccine and circulating strain may help inform the timing of booster doses if and when the vaccine antigen is updated.

In summary, we show substantial single-dose and strong and sustained two-dose mRNA VE against any infection among a large and diverse population of HCWs in acute and community care, spanning at least seven months of follow-up. Our findings reassure against marked waning of protection against infection per se, even among HCWs and despite VOC circulation, notably Delta. Such protection may have been facilitated by the Canadian decision to extend the interval between first and second doses, reinforcing that option in other jurisdictions or for future cohorts in the context of vaccine supply constraints and/or where urgent top-up of already substantial one-dose protection is less pressing. These findings among a potentially highly-exposed population may inform booster dose discussions more generally, particularly in considering the health and equity implications for HCWs, their patients, and others globally. Displayed are adjusted estimates of vaccine effectiveness against any SARS-CoV-2 infection, with 95% confidence interval (CI), by interval between first and second doses and time since second dose of any mRNA vaccine (in days/weeks) among health care workers (HCWs) in British Columbia, Canada. A conditional logistic regression model was used with adjustment for age group (18-29, 30-39, 40-49, 50-59, 60+ years), sex (male or female), and health authority of HCW's residence (Fraser Health Authority, Interior Health Authority, Northern Health Authority, Vancouver Island Health Authority, and Vancouver Coastal Health Authority) using the matching epiweek of testing as strata. Refer to Supplementary Table 3 for more details.

Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. The Lancet Public health

National Advisory Committee on Immunization (NACI). NACI rapid response: extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in the context of limited vaccine supply

Immunization manual. Part 4: Biological products. COVID-19 vaccines. Vancouver: BCCDC

A Higher Antibody Response Is Generated With a 6-to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval

Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses

Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. medRxiv preprint

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

British Columbia Centre for Disease Control (BCCDC)

Bridging the knowledge gap: an innovative surveillance system to monitor the health of British Columbia's healthcare workforce

Population projections

Infection control, occupational and public health measures including mRNA-based vaccination against SARS-CoV-2 infections to protect healthcare workers from variants of concern: A 14-month observational study using surveillance data

British Columbia Centre for Disease Control (BCCDC)

Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada

Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. The Lancet

BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study

Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States

Higher serological responses and increased vaccine effectiveness demonstrate the value of extended vaccine schedules in combatting COVID-19 in England

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. Cell Host & Microbe. 2021

Safety and Efficacy of the BNT162b2 mRNA Covid-19

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Authors thank Ms. Catherine Ogden and Mr. Jeffrey Phung for data access and assembly assistance and Dr. Solmaz Setayeshgar for programming assistance related to this work.

MK received grants/contracts paid to his institution from Roche, Hologic and Siemens, unrelated to this work. Other authors have no conflicts of interest to disclose.

Funding for this work was provided in part by the BCCDC Foundation for Public Health.

Data not publicly available.

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t Figure 2